[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolism-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolism-disorder":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100585253","metabolism-enhancement-by-laser-therapy-100585253",false,"NCT06899958","Metabolism Enhancement by Laser Therapy","MELT","Inclusion Criteria:\n\n1. 18- 60 years of age;\n2. BMI between 25.0 and 30 kg\u002Fm2;\n3. Subjects must be in good general health, based on answers provided during the screening visit;\n4. Subject must be able and willing to provide written informed consent and comply with the requirements of the study protocol.\n5. Females of childbearing potential must be willing and able to use a medically highly effective form of birth control during the entire study.\n\nExclusion Criteria:\n\n1. Participation in another investigational drug or device clinical trial in the past 30 days;\n2. Currently pregnant or pregnancy within the past 6 months or currently breastfeeding;\n3. Have a history of drug or alcohol abuse in the past 3 years or have reported habitual alcohol intake greater than 2 standard drinks per day (e.g., 2 beers, 2 glasses of wine, or 2 mixed drinks);\n4. Planning or currently participating in a weight loss program;\n5. Plan to change daily diet or level of physical activity;\n6. Intake of medication that may affect body weight such as GLP-1 receptor agonists, amitriptyline, bupropion, thyroid medications, etc.;\n7. History of cancer which required lymph node biopsy or dissection;\n8. Weight loss or gain of 10 kg or more in the past 6 months;\n9. History of diabetes mellitus or cardiac disease;\n10. Intake of hormone replacement therapy (HRT) in the last 6 months;\n11. Infection, surgery, or history of trauma or laser treatment to the treatment area in the past 6 months;\n12. Presence of any skin disease on the abdomen or thighs;\n13. Have birthmarks, tattoos, scars, or any other disfiguration of the skin in the abdomen or thighs;\n14. Presence of sunburn or tan in the abdomen or thighs;\n15. Use of any topical application of retinoids in the past 6 weeks on the abdomen or thighs or intake of systemic retinoids in the past 6 months;\n16. Use of any prescription topical medication, such as corticosteroids or hydroquinone on the abdomen or thighs in the past 6 weeks;\n17. History of keloid formation or hypertrophic scarring;\n18. History of bariatric surgery or other major weight-loss procedures;\n19. History of abdominal liposuction, abdominoplasty or CoolSculpting;\n20. Known allergy to lidocaine or other local anesthetics;\n21. The investigator believes that the subject is an unsuitable candidate to participate in the study, receive laser treatment, or would be placed at risk by participating in the study.",true,"ALL","18 Years","60 Years",{"count":21,"type":22},15,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a single-center, open-label pilot study to determine the effect of large area fractional laser treatment (LAFLT) on adults' metabolic profile.",[28],"Metabolism Disorder","NOT_YET_RECRUITING","2026-02-09",{"date":32,"type":33},"2026-02-11","ACTUAL",{"date":35,"type":22},"2027-01-01",{"date":37,"type":22},"2029-12-31",{"name":39,"class":40},"Massachusetts General Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":41},"100287065","umbilical-cord-blood-transplantation-from-unrelated-donors-100287065","NCT03016806","Umbilical Cord Blood Transplantation From Unrelated Donors","Inclusion Criteria:\n\n* Appropriate diagnosis: Patients must have a disease or syndrome amenable to therapy with hematopoietic stem cell transplantation. Diagnoses include, but are not limited to:\n* Congenital and Other Non-malignant Disorders:\n* Immunodeficiency disorders (e.g. Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome)\n* Congenital hematopoietic stem cell defects (e.g. Chediak-Higashi Syndrome, Congenital Osteopetrosis, Osteogenesis Imperfecta)\n* Metabolic disorders (e.g. Hurler's Syndrome)\n* Severe aplastic anemia\n* High-Risk Leukemia:\n* Acute Myelogenous Leukemia\n* Refractory to standard induction therapy (more than 1 cycle required to achieve remission)\n\n  * Recurrent (in CR ≥ 2)\n  * Treatment-related AML or MDS\n  * Evolved from myelodysplastic syndrome\n  * Presence of FLT3 abnormalities\n  * FAB M6 or M7\n  * Adverse cytogenetics\n  * Myelodysplastic Syndrome\n  * Acute Lymphoblastic Leukemia including T lymphoblastic leukemia:\n  * Refractory to standard induction therapy (time to CR \\>4 weeks)\n  * Recurrent (in CR ≥ 2)\n  * WBC count \\>30,000\u002FmcL at diagnosis\n  * Age \\>30 at diagnosis\n* Adverse cytogenetics, such as t(9:22), t(1:19), t(4:11), and other MLL rearrangements.\n* Chronic Myelogenous Leukemia in accelerated phase or blast crisis\n* Biphenotypic or undifferentiated leukemia\n* Burkitt's leukemia or lymphoma\n* Lymphoma:\n* Large cell, Mantle cell, Hodgkin lymphoma refractory or recurrent, chemo-sensitive, and ineligible for an autologous stem cell transplant or previously treated with autologous SCT\n* Marginal zone or follicular lymphoma that is progressive after at least two prior therapies\n* Multiple Myeloma, recurrent following high-dose therapy and autologous SCT or ineligible for an autologous HSCT\n* Solid tumors, with efficacy of allogeneic HSCT demonstrated for the specific disease and disease status\n* Adequate organ function:\n* Cardiac - LVEF \\>45%, or shortening fraction \\>25%, Absence of congestive heart failure or conduction disturbances with high risk for sudden death\n* Pulmonary - DLCO (corrected for hemoglobin), FEV1 and FVC ≥ 50% predicted;\n* Renal - serum Cr \\\u003C 1.5 times the upper limit of normal for age or GFR ≥ 50 ml\u002Fmin\u002F1.73m2\n* Hepatic - total bilirubin level \\\u003C 2 times the upper limit of normal (except for patients with Gilbert's syndrome or hemolysis); if the primary disease process is causal, this criterion will be reconsidered. ALT, AST, and Alkaline phosphatase ≤ 5 times upper limit of normal.\n* Performance Status Karnofsky or Lansky score ≥ 70%.\n* Informed Consent must be obtained prior to initiating conditioning therapy.\n* Receipt of viable cord blood product(s), single or dual, must be confirmed with the stem cell processing laboratory prior to initiating conditioning therapy.\n\nExclusion Criteria:\n\n* Availability of 10\u002F10 or 9\u002F10 HLA-matched related or unrelated donor within a reasonable timeframe dictated by the clinical urgency of the transplant\n* Autologous HSCT \\\u003C 6 months prior to proposed UCB transplant\n* Pregnant or breast feeding\n* Current uncontrolled infection\n* Evidence of HIV infection or positive HIV serology","2 Months","75 Years",{"count":51,"type":22},30,"OBSERVATIONAL","This study is being done to determine how long it takes for the engraftment (recovery of blood cell counts) of umbilical cord stem cells and also how often engraftment of umbilical cord stem cells transplanted from an unrelated donor fails. Another purpose will be to document the rate of disease-free survival and the rate of relapse (a return of your disease or syndrome) as well as the incidence and severity of graft versus host disease (GvHD) following cord blood stem cell transplantation. GvHD is a complication of stem cell transplants in which white blood cells from the transplanted tissue (graft) attack the transplant recipient's body (host).",[55,56,57,28,58,59,60,61,62,63],"Acute Leukemia","Immune Deficiency Disorder","Congenital Hematological Disorder","Aplastic Anemia","Myelodysplastic Syndromes","Chronic Leukemia","Lymphoma","Multiple Myeloma","Solid Tumor","RECRUITING","2025-10-08",{"date":67,"type":33},"2025-10-10",{"date":69,"type":4},"2015-06",{"date":71,"type":22},"2027-06",{"name":73,"class":40},"University of Rochester",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":41},"100569951","a-clinical-trial-to-assess-the-efficacy-and-tolerance-of-a-berberine-based-nutraceutical-formula-to-aid-blood-sugar-regulation-and-metabolism-100569951","NCT06700915","A Clinical Trial to Assess the Efficacy and Tolerance of a Berberine-based Nutraceutical Formula to Aid Blood Sugar Regulation and Metabolism","Inclusion Criteria:\n\n* Male or female.\n* BMI: 27-35 kg\u002Fm2\n* HbA1c of 5.7%-6.4% (determined by prescreening blood test)\n* Be generally healthy\n* Willing to refrain from taking any products, prescription medications, or supplements that target blood sugar regulation or metabolism during the test period.\n* Willing to maintain their current diet, sleep schedule, and activity level for the duration of the study.\n\nExclusion Criteria:\n\n* Diagnosed with Type 2 diabetes mellitus (T2DM) and have been prescribed metformin, insulin, Sulfonylureas, Meglitinides, SGLT2 inhibitors and\u002For GLP-1 medications including the following prescription medications: Wegovy (semaglutide), Ozempic (semaglutide), Rybelsus (semaglutide), Saxenda (liraglutide), Victoza (liraglutide), Zepbound (bimagrumab), Byetta (exenatide), Bydureon (exenatide ER), Trulicity (dulaglutide), Adlyxin (lixisenatide)\n* Current use or past history of use within the last 2 months (8 weeks) of the following prescription medications: Beta-blockers Sectral (Acebutolol), Tenormin (Atenolol), Kerlone, Betoptic (Betaxolol), Zebeta (Bisoprolol), Coreg, Coreg CR (Carvedilol), Trandate, Normodyne (Labetalol), Lopressor, Toprol XL (Metoprolol), Corgard (Nadolol), Bystolic (Nebivolol), Levatol (Penbutolol), Visken (Pindolol), Inderal, Inderal LA, InnoPran XL (Propranolol). Thiazide diuretics Diuril (Chlorothiazide), Microzide (Hydrochlorothiazide), Thalitone, Hygroton (Chlorthalidone), Lozol (Indapamide), Zaroxolyn (Metolazone), Naturetin (Bendroflumethiazide), Enduron (Methyclothiazide). Corticosteroids Deltasone (Prednisone), Orapred, Prelone (Prednisolone), Medrol (Methylprednisolone), Qvar (Beclomethasone), Celestone (Betamethasone), Decadron (Dexamethasone), Cortef (Hydrocortisone), Kenalog (Triamcinolone). Immunosuppressants Tacrolimus (Prograf), Cyclosporine (Neoral), Sirolimus (Rapamune)\n* Women who are pregnant, breastfeeding, or trying to conceive.\n* Anyone unwilling or unable to follow the study protocol.\n* Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.\n* Is currently undergoing or planning to undergo any significant medical procedures in the next six months\n* Has had any major illness in the last three months.\n* A history of severe allergic reactions, including but not limited to any of the product's ingredients.\n* Heavy drinkers or drug users. A heavy drinker is considered to be a woman who drinks 8 or more alcoholic drinks per week or a man who drinks 15 or more alcoholic drinks per week.\n* Impaired hepatic function.\n* Individuals taking prescription or over-the-counter medication, or herbal remedies that affect blood sugar regulation or metabolism.\n* Currently being treated for an infection with an antibiotic and\u002For antiviral prescription medication.","70 Years",{"count":82,"type":22},80,[25],"This randomized, triple-blind, placebo-controlled study will evaluate the efficacy of Diaberine, a berberine-based nutraceutical, in aiding blood sugar regulation and metabolism in 80 participants over 24 weeks.",[28,86],"Nutraceutical",[88,89],"Blood Sugar Regulation","Berberine","2024-12-09",{"date":92,"type":33},"2024-12-13",{"date":94,"type":33},"2024-10-03",{"date":96,"type":22},"2025-05-01",{"name":98,"class":99},"Ultimate International, Inc.","INDUSTRY"]